MRUS News and Press, Merus N.V. From 12/16/19

— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer — — Ton Logtenberg, Ph.D., to step down after 16 years of leadership — — Transition to occur December 31, 2019 — UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2019 ...

Merus N.V. (NASDAQ: MRUS), a clinical-stage bispecific antibody company developing Biclonics(R), has closed an underwritten public offering of 5,462,500 of its common shares, which includes 712,500 additional shares per the full exercise of the over-allotment option granted to the underwriters...

Merus (NASDAQ: MRUS ): Q3 GAAP EPS of -€0.35  beats by €0.15 . More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Bic...

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offeri...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics ® , today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shar...

Gainers:  Tiffany & Co. (NYSE: TIF ) +31% . Xunlei Limited (NASDAQ: XNET ) +27% . Datasea (NASDAQ: DTSS ) +25% . comScore (NASDAQ: SCOR ) +24% . Fitbit (NYSE: FIT ) +23% . Aquestive Therapeutics (NASDAQ: AQST ) +23% . ChinaNet Online Holdings (NASDAQ: CNET ) +20% . Libbey (...

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Of nine patients enrolled across the MCLA-128 Early Acc...

One out of every eight women in the United States will develop breast cancer, according to Breastcancer.org. Of those, about 25% will have an aggressive type called "HER2-positive," which also recurs at higher rates. The human epidermal growth factor receptor 2 (HER2) gene produces proteins tha...

UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length h...